ZOMETA® Case Study: Renal Cell Carcinoma (RCC) Medical Profile – Carlo Is Not Alone

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study – Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

Page

1 2 3

Carlo is not alone

20% to 25% of patients with advanced renal cell carcinoma will develop bone metastases¹
74% of patients with renal cell carcinoma and bone metastases will experience a skeletal-related event (SRE) without treatment²
SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumor-induced hypercalcemia³

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.